GRIFOLS Executive and Leadership Team

Christopher Healey, the President at GRIFOLS, directs the overarching strategic vision and operational execution across the global enterprise. Healey guides the company's expansion into new markets, ensuring alignment with Grifols' mission to improve health and well-being. This leadership role involves fostering innovation within the Bioscience, Diagnostic, Hospital, and Bio Supplies divisions, driving growth and maintaining Grifols' position as an industry reference for quality and safety. Healey's strategic direction supports the company's long-term, sustainable, and responsible perspective across the entire value chain. By focusing on donor and patient well-being, Christopher Healey ensures that all initiatives contribute directly to enhancing people's lives globally. The President's oversight extends to cultivating a diverse and skilled team, recognizing its critical importance for future success and reinforcing Grifols' commitment to ethical operations.

William Zabel, the Sales & Commercial Operations President (North America) at GRIFOLS, spearheads all sales initiatives and commercial strategies within the vital North American region. Zabel drives revenue growth and market penetration for Grifols' diverse portfolio of plasma-derived medicines and healthcare solutions. This executive oversees the intricate network of sales teams and commercial operations, ensuring seamless product delivery and exceptional customer engagement. By optimizing sales channels and commercial strategies, William Zabel directly contributes to Grifols' objective of being a global leader in its markets. The focus remains on expanding market reach and reinforcing Grifols' reputation for quality and innovation in one of its most significant operational territories. Zabel's leadership ensures that the company's commitment to improving health and well-being is effectively translated into commercial success across North America.

Roland Wandeler, the President Biopharma at GRIFOLS, directs the strategic growth and operational excellence of the Biopharma division, a cornerstone of Grifols' plasma-derived medicines business. Wandeler spearheads initiatives focused on expanding the reach and impact of Grifols' innovative therapies, ensuring they meet the needs of patients worldwide. This leadership role involves driving research and development efforts, optimizing manufacturing processes, and forging key partnerships to enhance the division's market position. Roland Wandeler's focus on innovation and quality directly supports Grifols' commitment to improving health and well-being. By leading the Biopharma division, Wandeler plays a crucial part in Grifols' mission to be a global leader, emphasizing a long-term, sustainable, and responsible perspective in all operations and product development.

Marilyn Rosa, the Chief Medical Officer & Global Senior VP, Plasma Quality & Regulatory Affairs at GRIFOLS, governs the critical medical strategy and ensures the highest standards of plasma quality and regulatory compliance worldwide. Rosa leads the scientific and medical affairs functions, providing essential expertise that underpins Grifols' product development and patient safety initiatives. This senior leadership position involves meticulous oversight of all regulatory submissions and adherence to global health authority requirements, safeguarding the integrity of Grifols' plasma-derived medicines. Marilyn Rosa's dedication to quality ensures that Grifols maintains its industry reference status for safety and innovation. By championing rigorous quality control and robust regulatory frameworks, Rosa directly supports the company's mission to improve the health and well-being of people globally, reinforcing Grifols' ethical approach and long-term sustainable perspective.